Nearly three-quarters of people with migraine in Japan may have potential unmet needs for acute treatment.

OVERCOME (Japan) was a cross-sectional, population-based web survey of people with migraine in Japan.

Survey questions included:
- Current acute medication use
- Medication effectiveness (mTOQ-4)
- Cardiovascular history and risk factors

17,071 people with migraine completed the survey.

Effectiveness of current acute treatment (respondents’ assessments):
- Very poor: 6.5%
- Poor: 41.6%
- Moderate: 35.0%
- Maximum: 16.9%

Potential unmet needs in acute treatment of migraine in Japan:
- ≥1 potential unmet need: 74.1%
- Insufficient efficacy (mTOQ-4 ≤5): 42.0%
- Former triptan users: 5.3%
- Triptan contraindication: CV event or procedure: 10.3%
- ≥1 CV risk factor: 52.9%

CV cardiovascular, mTOQ-4 4-Item Migraine Treatment Optimization Questionnaire, NSAID nonsteroidal anti-inflammatory drug.

Takao Takeshima, Kaname Ueda, Mika Komori, Anthony J. Zagar, Yongin Kim, Dena H. Jaffe, Yasuhiko Matsumori, Koichi Hirata

The graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online. ©The authors, CC-BY-NC 2022.